SMTL ID : 3sie.1 (1 other biounit)

Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.93 Å

Oligo State

monomer

Ligands

1 x 5BO: 5-bromo-6-ethyl-2-{5-[(4-methylpiperazin-1-yl)sulfonyl]-2-propoxyphenyl}pyrimidin-4(3H)-one(Non-covalent)

5BO.1: 11 residues within 4Å: Chain A: Y.99, A.266, V.269, A.270, F.273, L.291, I.300, M.303, Q.304, G.306, F.307 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:Y.99, A:A.266, A:V.269, A:L.291, A:I.300, A:M.303, A:F.307, A:F.307 Hydrogen bonds: A:Q.304, A:Q.304 pi-Stacking: A:F.307 Halogen bonds: A:Y.99

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Xu, Z. et al., Utilization of Halogen Bond in Lead Optimization: A Case Study of Rational Design of Potent Phosphodiesterase Type 5 (PDE5) Inhibitors. J.Med.Chem. (2011)

Release Date

2011-08-24

Peptides

cGMP-specific 3',5'-cyclic phosphodiesterase: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

cGMP-specific 3',5'-cyclic phosphodiesterase

Related Entries With Identical Sequence